Skip to main content
Clinical Trials/NCT02301260
NCT02301260
Completed
Not Applicable

Speed of Processing Training to Improve Cognition in Multiple Sclerosis: A Randomized Clinical Trial

Kessler Foundation1 site in 1 country100 target enrollmentApril 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Multiple Sclerosis
Sponsor
Kessler Foundation
Enrollment
100
Locations
1
Primary Endpoint
Change in scores on standardized tests of processing speed
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

The purpose of this research study is to investigate the effectiveness of a computerized technique designed to improve processing speed (i.e. the amount of time it takes for a person's brain to process information) in a multiple sclerosis (MS) population. The study is designed to study how well this technique can help people with MS increase their processing speed and their ability to function better in everyday life. This treatment protocol has been studied extensively with older adults, showing improvements on standard laboratory measures of processing speed and performance of activities of daily living.

Detailed Description

This study is a double-blind, placebo-control randomized clinical trial examining the efficacy of Speed of Processing Training (SPT) for improving processing speed (PS) deficits in persons with Multiple Sclerosis (MS). Slowed PS is one of the most common deficits in individuals with MS and such deficits have been shown to exert significant negative impact on multiple aspects of everyday life, including occupational and social functioning. Despite these findings, few studies have attempted to remediate PS deficits in order to improve the everyday functioning of individuals with MS. This study is designed to (1) apply a treatment protocol for PS impairments well-validated in an aging population to individuals with MS with objectively observable deficits in PS and document its efficacy on standard neuropsychological outcome measures. In addition, the investigators will (2) assess the effectiveness of the intervention utilizing global measures of everyday life, including an objective measure (the Timed Activities of Daily Living; TIADL), as well as additional questionnaires to be completed by both the participant and a significant other. This study is also designed to (3) examine the influence of degree of PS impairment on treatment efficacy using neuropsychological tests, (4) evaluate the long-term effects of the treatment protocol and (5) examine the utility of booster sessions to facilitate long-term treatment effects.

Registry
clinicaltrials.gov
Start Date
April 2014
End Date
February 2020
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Kessler Foundation
Responsible Party
Principal Investigator
Principal Investigator

Nancy Chiaravalloti

Director, Neuropsychology and Neuroscience Laboratory

Kessler Foundation

Eligibility Criteria

Inclusion Criteria

  • English as a primary language
  • diagnosis of Multiple Sclerosis
  • processing speed impairment (based on evaluation)

Exclusion Criteria

  • most recent exacerbation within one month
  • currently taking steroids or benzodiazepines
  • history of significant psychiatric illness (bipolar disorder, schizophrenia, or psychosis) or a current diagnosis of Major Depressive Disorder
  • significant alcohol or drug abuse history

Outcomes

Primary Outcomes

Change in scores on standardized tests of processing speed

Time Frame: Three points in time: baseline (week1), immediately following treatment (week 7) and 6 months after treatment is completed

Secondary Outcomes

  • Change in scores on self-report of quality of life, measured via questionnaire(Three points in time: baseline (week1), immediately following treatment (week 7) and 6 months after treatment is completed)
  • Change in scores on self-report of emotional functioning, measured via questionnaire(Three points in time: baseline (week1), immediately following treatment (week 7) and 6 months after treatment is completed)
  • Change in scores on self-report of everyday functioning, measured via questionnaire(Three points in time: pre-treatment, immediately following treatment and 6 months after treatment is completed)

Study Sites (1)

Loading locations...

Similar Trials